Cellular Biomedicine Starts China Trial of CAR-T Drug for Multiple Myeloma

Cellular Biomedicine, a Shanghai immunotherapy/stem cell company, has started a China trial of its anti-BCMA CAR-T therapy in patients with relapsed and refractory multiple myeloma. The Phase I trial will enroll 22 patients to evaluate the safety and efficacy of the candidate. In 2018, Novartis chose CBMG to be its China manufacturer of Kymriah®, an approved CAR-T therapy. Novartis invested $40 million in CBMG for a 9% stake in the company as part of the agreement. More details.... Stock Symbols: (NSDQ: CBMG) (NYSE: NVS) Share this with colleagues: // //